Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

PURPOSE: We hypothesized that bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), will potentiate the activity of pemetrexed, a multitargeted antifolate, in squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS: Patients with previously untreate...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Argiris, Athanassios, Karamouzis, Michalis V., Gooding, William E., Branstetter, Barton F., Zhong, Shilong, Raez, Luis E., Savvides, Panayiotis, Romkes, Marjorie
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Clinical Oncology 2011
Onderwerpen:
Original Reports
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3083869/
https://ncbi.nlm.nih.gov/pubmed/21343546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.33.3591
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items